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Abstract
Deregulated expression of the hepatocyte growth factor (HGF) receptor, c-Met, in cancer contributes to tumor
progression and metastasis. The objective of this study was to determine whether blocking c-Met with an orally
available c-Met inhibitor, PF-2341066, reduces tumor burden and increases survival in a xenograft model of ovarian
cancer metastasis. Treatment of mice injected interperitoneally with SKOV3ip1 cells showed reduced overall tu-
mor burden. Tumor weight and the number of metastases were reduced by 55% (P < .0005) and 62% (P < .0001),
respectively. Treatment also increased median survival from 45 to 62 days (P = .0003). In vitro, PF-2341066 re-
duced HGF-stimulated phosphorylation of c-Met in the tyrosine kinase domain as well as phosphorylation of
the downstream signaling effectors, Akt and Erk. It was apparent that inhibition of the pathways was functionally
important because HGF-induced branching morphogenesis was also inhibited. In addition, proliferation and ad-
hesion to various extracellular matrices were inhibited by treatment with PF-2341066, and the activity of matrix
metalloproteinases was decreased in tumor tissue from treated mice compared with those receiving vehicle. Over-
all, these data indicate that PF-2341066 effectively reduces tumor burden in an in vivo model of ovarian cancer
metastasis and may be a good therapeutic candidate in the treatment of patients with ovarian cancer.
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Introduction
Ovarian cancer has the highest mortality rate of any gynecologic ma-
lignancy and is the fifth leading cause of cancer death in women [1].
Current treatment protocols for patients with advanced stage disease
involve surgical debulking followed by six cycles of intravenous or intra-
peritoneal platinum-based chemotherapy [2]. Despite this aggressive
treatment, the average time of clinical remission is just 2.5 years [3]
and approximately 20% of women never achieve remission [2]. These
statistics clearly underscore the need to identify new molecular targets
that can be translated to the clinical treatment of women with ovar-
ian cancer.
c-Met is a receptor tyrosine kinase with one high-affinity ligand,
hepatocyte growth factor/scatter factor (HGF/SF). On binding of
HGF, c-Met undergoes dimerization and tyrosine residues in the cyto-
plasmic domain are transphosphorylated, generating docking sites for
SH2-containing adapter proteins including Grb2, Shc, c-Cbl, and
Gab1. The adaptor proteins then recruit intracellular signaling trandu-
cers that activate, among others, ras-mitogen-activated protein kinase
(MAPK), phosphatidylinositol 3-kinase (PI3K), and the signal trans-
ducers and activators of transcription signaling pathways [4,5]. Activa-
tion of the pathways results in a plethora of biologic responses such
as proliferation, cell cycle progression, migration, angiogenesis, and in-
vasion, all of which contribute to the tumorigenicity of cancer cells.
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In normal physiology, the expression of c-Met is constrained to ep-
ithelial cells, whereas the expression and secretion of HGF is restricted
to stromal cells. Overexpression of the receptor and its ligand has been
implicated in a number of different cancers, including those of the
breast, gastric system, and lung [4]. We have previously shown that
c-Met is overexpressed in ovarian cancer and that its targeting by small
interfering RNA (siRNA) inhibited adhesion, invasion, peritoneal dis-
semination, and tumor growth in vivo by blocking the fibronectin re-
ceptor α5β1 [6]. In addition, we and others have shown a relationship
between advanced stage disease, poor prognosis, and increased expres-
sion of c-Met in ovarian cancer [6–9]. Approximately 40% to 60% of
all tumors from patients with ovarian cancer overexpress c-Met [8–11].
These data suggest that c-Met could be an important therapeutic target
in the treatment of ovarian cancer, justifying the exploration of anti–
c-Met treatment strategies for this disease.
Several strategies aimed at inhibiting both c-Met and HGF are
currently being pursued. HGF variants, c-Met decoy receptors, neu-
tralizing antibodies and small-molecule inhibitors have proven to be
effective in inhibiting c-Met signaling in preclinical models of certain
human tumors [12,13]. For example, a monoclonal antibody against
c-Met, MetMAb, functions by blocking HGF from binding to the
receptor and the subsequent activation of the signaling pathway.
MetMAb was found to have potent antitumor activity and to in-
crease survival in an orthotopic model of pancreatic cancer [14].
Whereas many small-molecule inhibitors of c-Met have been identi-
fied [15–17], these inhibitors often fail to reach the clinic because of
poor bioavailability.
Given the many preclinical studies that indicate that the inhibition
of c-Met is a viable therapeutic strategy, and the consistent finding
that c-Met overexpression has prognostic value in ovarian cancer, we
sought to determine the efficacy of an orally available inhibitor (PF-
2341066) against c-Met in ovarian cancer. PF-2341066 is a novel
small-molecule inhibitor highly specific against c-Met and anaplastic
lymphoma kinase (ALK). Zou et al. showed that it is a potent ATP-
competitive inhibitor of human c-Met kinase with a mean K i of
4 nM [18,19]. Evaluation of the inhibitor against more than 120
different kinases revealed that PF-2341066 is more than 100 times
more selective toward c-Met than the majority (>90%) of kinases
tested. In addition, the inhibitor displayed potent activity against
mutant c-Met variants that had been previously found to contribute
to oncogenesis [20].
In the present study, we demonstrate that PF-2341066 reduces
tumor burden and increases survival in a mouse model of ovarian
cancer. The antitumor activity of PF-2341066 is mediated, at least
in part, by reduced proliferation, adhesion, invasion, and induction
of apoptosis.
Materials and Methods
Reagents and Cell Lines
PF-2341066 was provided by Pfizer Global Research and Devel-
opment (La Jolla, CA) [19]. The extracellular matrices (ECMs), col-
lagen type 1, fibronectin, and vitronectin and the antibody against
total FAK were purchased from BD Biosciences (Bedford, MA).
Anti–phospho-c-Met (Tyr1230/1234/1235 and Tyr1003) and phospho-
FAK (Tyr861) polyclonal antibodies for immunoblot analysis were ob-
tained from BioSource International (Camarillo, CA). Total c-Met
(C-28) and normal mouse immunoglobulin G were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Total Src and phospho-
Src were purchased from Millipore (Billerica, MA). Antibodies against
phospho-Gab1,Gab-1, phospho-c-Met (Tyr1349) p44/42MAPK,phospho-
p44/42 MAPK (Thr202/Tyr204), Akt, phospho-Akt (Ser473), β-actin,
and horseradish peroxidase–conjugated secondary antibodies were pur-
chased from Cell Signaling (Beverly, MA). The human ovarian can-
cer cell line CaOV3 was purchased from the American Type Culture
Collection (Rockville, MD). SKOV3ip1 and HeyA8 cells were from
Dr. Gordon B. Mills (MD Anderson Cancer Center, Houston, TX).
Xenograft Model
SKOV3ip1 cells (1 × 106) were injected i.p. into 5- to 7-week-old
female athymic nude mice (NCI-Fredrick, MD) [21]. For the studies
with a defined end point, tumors were allowed to grow for 8 days after
injection and then treatment with 50 mg/kg PF-2341066 or the
vehicle (water, pH 4.0) began. Treatment lasted for 35 days and was
given 6 days/week by oral gavage. At the end of the treatment period,
the mice were killed, and tumor burden was analyzed by excision
of the tumors to determine total tumor weight and the number of
metastasis. Tissue for the zymogram was snap-frozen and then stored
at −80°C until processed. For the survival study, mice were injected
i.p. with SKOV3ip1 cells and treatment with 50 mg/kg PF-2341066
or the vehicle began 8 days after injection. Treatment was continued
p.o. 6 days/week, until mice began to show signs of distress (weight
loss, ascites, reduced activity) and required euthanization. After 78 days
(10 weeks) of survival, all remaining mice were killed, and the presence
of tumor was confirmed. Three of the treated mice were censored. In
addition, three control mice were not included in the analysis because
they never developed tumors. Procedures involving animals were ap-
proved by the Institutional Committee on Animal Care, University
of Chicago.
Western Blot Analysis
For c-Met and downstream signaling proteins, cells were starved in
serum-free medium before being stimulated with HGF/SF (40 ng/ml).
Cells were lysed using ice-cold RIPA buffer (150 mM NaCl, 50 mM
Tris-HCl; pH 7.5, 1% deoxycholate, 0.1% SDS, 1% Triton X-100,
1 mM PMSF, 1 mM Na3VO4, protease inhibitor cocktail (1:1000;
Sigma)). An equal amount (15 μg) of cell extracts was separated by
4% to 20% gradient SDS-PAGE and transferred to nitrocellulose mem-
branes. The transferred samples were incubated with the primary anti-
body, as indicated in the figure legends, and then incubated with the
corresponding secondary horseradish peroxidase–conjugated immuno-
globulin G. The proteins were then visualized with enhanced chemilu-
minescence reagents. Blots were stripped and reprobed for β-actin.
Branching Morphogenesis Assay
The assay was performed as previously described [22]. Briefly,
2000 cancer cells were seeded in 100 μl of a 1:1 mix of growth factor–
reduced Matrigel and serum free DMEM, in a 96-well plate. The
Matrigel plug was allowed to gel for 30 minutes at 37°C. Then, 100 μl
of the medium supplemented with FBS, 40 ng/ml of HGF, and 1 μM
PF-2341066 or vehicle was placed on top. The cells were then cultured
for 4 days, and pictures were taken using an Axiovert 100 microscope
(Zeiss, Göttingen, Germany) at 20×. Medium was changed daily.
Proliferation Assay
The proliferation of ovarian cancer cells was measured using the
CyQuant cell proliferation assay kit (Molecular Probes, Eugene, OR).
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The CyQuant GR fluorescence dye shows strong fluorescence enhance-
ment when bound to nucleic acids. SKOV3ip1 or HeyA8 (3 × 103)
were seeded in 96-well plates and cultured in the presence of PF-
2341066 or an equivalent volume of vehicle. At the indicated time
points, cells were washed once with PBS and frozen at −80°C. Cells
from each time point were lysed in a buffer containing the fluorescent
dye. Fluorescence was measured using a fluorescence spectrophotom-
eter (Synergy HT; Bio-Tek, Winoosky, VT) multiwell fluorescence
plate reader at 485 nm excitation and 530 nm emission.
Nuclear Fragmentation to Determine Apoptosis
HeyA8 cells were treated for 48 hours with 10 μM PF-2341066 or
vehicle. Cells were rinsed and then fixed with 4% formaldehyde for
15 minutes at room temperature (RT). After fixation, the cells were
rinsed twice with Hank’s balanced salt solution and then incubated
with 2 μM Hoechst 33342 stain (Molecular Probes) for 10 minutes
at 37°C. Cells were visualized at 20× using an Axiovert 100 equipped
with a digital camera.
Apoptosis and Cell Cycle Analysis
To determine the amount of apoptosis after PF-2341066 treatment,
HeyA8 cells were treated for 48 hours with 10 μM PF-2341066 or
vehicle. For analysis of cell cycle, HeyA8 cells were serum-starved
for 24 hours before treatment with 10 μM PF-2341066 or vehicle
for 24 hours. The total cell population was collected, fixed in 70%
EtOH, resuspended in propidium iodide staining solution, and stained
for 30 minutes in the dark at RT. The samples were then analyzed
by flow cytometry for sub-G1, G1, S, and G2/M populations using
FlowJo software.
In Vitro Adhesion Assay to ECM Components
Ovarian cancer cells were fluorescently labeled with 10 μMCMFDA
(green) (Molecular Probes) and then pretreated with 10 μM PF-
2341066 for 10 minutes in serum-free media. Cells (5 × 104) were
plated in a 96-well plate that had been precoated with collagen type
1 (50 μg/ml), fibronectin (5 μg/ml), or vitronectin (5 μg/ml). After
incubating for 30 minutes at 37°C, cells were washed three times
(PBS) and fixed with 4% paraformaldehyde for 10 minutes at RT.
The number of adhesive cells was quantified by measuring the fluores-
cent intensity (Ex = 590 nm, Em = 620 nm) with a fluorescence spec-
trophotometer (Synergy HT; Bio-Tek).
Gelatin Zymogram
Snap-frozen tumors were pulverized using a mortar and pestle in
liquid nitrogen and then lysed in eight-fold volume of RIPA buffer in
the absence of a reducing agent [23]. Protein concentrations were
determined using Pierce bicinchoninic acid protein assay (Thermo
Scientific, Rockford, IL). Equal amounts of protein (30 μg) from
three treated and three control mice were combined and resolved
on a 10% SDS–polyacrylamide gel containing 0.1% (wt/vol) gelatin
as substrate (Bio-Rad, Hercules, CA). The gel was then rinsed in
Triton-X buffer (2.5% Triton X-100, 50 mM Tris-HCl (pH 7.5),
0.05% NaN3) for 2 hours at RT with gentle shaking to rinse out
the SDS and allow the protein to renature. Then the gel was incu-
bated overnight at 37°C in incubation buffer (0.15 M NaCl, 50 mM
Tris-HCl, 10 mM CaCl2, 0.05% NaN3) that activates the collagen-
ase. After the overnight incubation, the gel was stained with 0.25%
Coomassie blue (45.5% MeOH, 1.1% AcCOOH) for 45 minutes
at RT. After staining, the gel was destained with a solution containing
10% AcCOOH and 25%MeOH for 3 hours at RTwith three washes
on a shaker until contrast is satisfactory. Conditioned medium from
HT-1080 cells was used as a positive control for the full and active
forms of matrix metalloproteinases 9 and 2 (MMP-9 and MMP-2).
Proteolysis was detected as a white zone in a dark field.
Immunohistochemistry
Tumors extracted frommouse omentumwere formalin-fixed, paraffin-
embedded, sectioned, and mounted on slides. To retrieve antigens,
slides were boiled in 0.01 M sodium citrate pH 5.0 for 20 minutes.
All slides were blocked in avidin and biotin blocking solutions (Vector
Laboratories, Burlingame, CA). Slides were stained with hematoxylin
and eosin (H&E) or incubated with primary antibodies against Ki-67
(1:300; LABVISION, Fremont, CA) and CD31 (1:200; Santa Cruz
Biotechnology) for 1 hour. After three washes in Tris-buffered saline
(TBS), the slides were incubatedwith the species-appropriate biotinylated
secondary antibody (1:500). Again, the slides werewashedwithTBS then
incubated with peroxidase-linked avidin using the Vectastain ABC kit
(Vector Laboratories) for 30 minutes. The slides were rinsed in TBS
and stained with 3-3-diaminobenzidine chromogen. Negative controls
were prepared by omitting the primary antibody.
Statistical Analysis
Overall survival estimates were computed using the Kaplan-Meier
method, and comparisons between groups were analyzed using the
log-rank test. Significant changes were determined by two-sided, un-
paired t test.
Results
PF-2341066 Inhibits In Vivo Tumor Growth
As a first step toward determining the potential therapeutic effi-
ciency of PF-2341066, we used an ovarian cancer xenograft model
in which SKOV3ip1 ovarian cancer cells are injected intraperitone-
ally (i.p.) into the abdominal cavity of nude mice [21]. After tumors
were established for 8 days, mice underwent oral treatment with
either PF-2341066 or the vehicle for 4 weeks. In mice treated with
the inhibitor, the number of metastases (Figure 1A) was reduced by
63% (P < .0001) and the overall tumor weight (Figure 1B) was re-
duced by 55% (P < .0005) compared with the control mice. There
was no significant difference in the ascites volume between treated and
control groups (data not shown). Microscopic evaluation of H&E-
stained tumors revealed large areas of necrosis in tumors from treated
mice (Figure 1C ). The effect of the inhibitor on proliferation (Ki-67)
and angiogenesis (CD31) was evaluated by immunohistochemistry.
Tumors from treated mice had a marked reduction in Ki-67 staining
(Figure 1C ) compared with the control tumors; however, there was
no significant change in CD31 staining (data not shown). Because
treatment with PF-2341066 significantly reduced tumor burden, we
sought to determine whether treatment could also increase survival
time. Mice with established i.p. tumors were treated either with
PF-2341066 or vehicle for 10 weeks. Treatment with the c-Met inhib-
itor increased the median survival time of mice to 62 days compared
with the mice receiving vehicle, which became distressed after 45 days
(Figure 2). Log-rank analysis (Kaplan-Meier) showed that the survival
benefit from treatment with PF-2341066 was significant (P = .0003).
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Effects of PF-2341066 on c-Met Phosphorylation and
Downstream Signaling in Ovarian Cancer Cell Lines
PF-2341066 had been previously shown to be a potent inhibitor
of c-Met and NPM-ALK kinase [18,19]. A thorough review of the
literature and available databases revealed that ALK or its oncogenic
fusion variants have never been shown to be expressed or active in
ovarian cancer tumors. We confirmed this by Western blot analysis
showing that ovarian cancer cell lines do not express ALK or ALK-
fusion proteins compared with lysates from an anaplastic large cell
lymphoma (ALCL) cell line, SUDHL-1 (Figure 3A). We therefore fo-
cused our studies of PF-2341066 in ovarian cancer on its anti–c-Met
effect. Stimulation with HGF leads to activation of c-Met and sub-
sequent activation of MAPK, PI3K, and signal transducers and acti-
vators of transcription signaling pathways that mediate the biologic
Figure 1. Treatment with PF-2341066 reduces tumor burden in an ovarian cancer xenograft model. Female athymic nude mice bearing
SKOV3ip1 i.p. tumors (8 days) were given PF-2341066 at 50 mg/kg or vehicle 6 days/week by oral gavage for 5 weeks. At the end of the
experiment, tumors were counted to determine tumor number (A) and weighed (B) to assess tumor burden. Each square indicates
individual mouse (right). (A, B) Treated n = 12, control n = 10. *P < .0001, **P < .0005. (C) Immunohistochemistry of tumors from
control- and PF-2341066–treated mice. H&E, Ki-67, and negative control are shown. Representative pictures are shown for the treatment
groups. Original magnification, ×200. Scale bar, 200 μm. **Area of necrosis in PF-2341066–treated tumors.
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effects of c-Met activation [4,5]. Therefore, we sought to understand
if PF-2341066 inhibits the HGF/c-Met signaling pathway. Three
ovarian cancer cell lines (CaOV3, SKOV3ip1, and HeyA8) were pre-
treated with the indicated doses of PF-2341066 before stimulation
with HGF. All three cell lines expressed c-Met, the highest expression
occurring in CaOV3 cells (Figure 3B). Pretreatment with 50 nM PF-
2341066 was sufficient to block HGF induced c-Met phosphoryla-
tion by more than 50% in all three cell lines (Figure 3B). Complete
inhibition of c-Met was achieved in both CaOV3 (Figure 3B, left
panel ) and SKOV3ip1 (Figure 3B, middle panel ) cells with a 1-μM
dose as shown by an absent phosphorylation of tyrosine residues
1230/1234/1235, which are localized in the tyrosine kinase domain.
PF-2341066 blocked the phosphorylation of Akt and Erk1/Erk2,
suggesting inhibition of the c-Met–dependent pathways, PI3K and
Erk-MAPK (Figure 3B).
The HeyA8 ovarian cancer cells [24] behaved differently than the
SKOV3ip1 and CaOV3 cells: phosphorylation of c-Met at residues
in the kinase domain (1230/34/35) could only be partially inhibited
by the highest dose of PF-2341066, and the inhibitor had no effect
on the phosphorylation of Erk1/Erk2. However, the phosphorylation
of Akt was clearly inhibited by PF-2341066 (Ser 473) (Figure 3B,
right panel ). Further analysis of HeyA8 signaling revealed that the
inhibitor reduced c-Met phosphorylation in unstimulated cells at
the Gab-1 (Grb2-associated binding protein-1) binding site, tyrosine
1349 (Figure 3C ). Activation of the known downstream signal trans-
ducers, Gab-1 and Src, were both inhibited by treatment with PF-
2341066 (Figure 3C ). In addition, phosphorylation of FAK (focal
adhesion kinase) at the major Src binding site, 861, was reduced
by the inhibitor.
The biologic effect of c-Met activation results in a morphogenic re-
sponse known as “invasive growth.” This can be visualized using the
branching morphogenesis assay that measures the ability of cells to
grow and invade in a three-dimensional matrix [22]. To determine the
effect of PF-2341066 treatment on branching morphogenesis, HeyA8
and SKOV3ip1 cells were seeded within a three-dimensional matrix. In
the presence of HGF, the cells formed multicellular-branched struc-
tures (Figure 3D). Addition of the inhibitor, PF-2341066, was sufficient
to inhibit branching morphogenesis in both HeyA8 and SKOV3ip1
cells (Figure 3D).
PF-2341066 Inhibits Adhesion and Invasion of Ovarian
Cancer Cells
One of the key steps in ovarian cancer metastasis is the attachment
of cancer cells to peritoneal surfaces within the abdominal cavity,
most commonly the peritoneum and omentum [25]. We had previ-
ously shown that silencing c-Met with siRNA reduced the adhesion
of ovarian cancer cells to peritoneum and different ECMs [6]. There-
fore, we analyzed the effect of c-Met inhibition by PF-2341066 on
ovarian cancer cell adhesion to several ECMs previously shown to be
involved in early ovarian cancer metastasis [26]. Fluorescently labeled
ovarian cancer cells were pretreated with PF-2341066 or vehicle
(mock) and then allowed to adhere to plastic, collagen type I, fibro-
nectin, or vitronectin. The number of adherent cells was quantified
by measuring fluorescence, which represents the number of attached
cells (Figure 4A). Treatment with the c-Met inhibitor significantly
reduced the adhesion of both SKOV3ip1 and HeyA8 (Figure 4A)
to all the ECMs, with the most significant inhibition shown in ad-
hesion to fibronectin. MMPs have been shown to play an important
role in tumor progression in vitro and in animal models. Beyond
their ability to facilitate migration and invasion through degradation
of ECMs, they are also known to release mitogenic growth factors
from cell surfaces and from ECM reservoirs and to regulate tumor-
associated angiogenesis [27]. The expression of MMP-2 and MMP-9,
in particular, has been shown to correlate with a greater metastatic po-
tential in ovarian tumors [28]. Therefore, to determine whether the
activity of key proteases is reduced by treatment with PF-2341066,
we analyzedMMP-2/9 gelatinolytic activity in SKOV3ip1 tumor xeno-
grafts from Figure 1 using zymography. Tumors from vehicle-treated
mice were found to secrete an 83-kDa gelatinase indistinguishable in
size from the active form of MMP-9 (Figure 4B) and a 66-kDa gela-
tinase consistent with the active form of MMP-2. Tumors from mice
treated with PF-2341066 displayed reduced activity of both enzymes
when compared with the tumors from control mice (Figure 4B).
Treatment with PF-2341066 Reduces Ovarian Cancer Cell
Growth and Induces Apoptosis
Key mediators of tumor progression are proliferation and resis-
tance to apoptosis. A fluorescence-based proliferation assay was used
to determine whether treatment with PF-2341066 inhibits ovarian
cancer cell growth. The two ovarian cancer cell lines, SKOV3ip1
and HeyA8, were treated with either PF-2341066 or vehicle (mock).
A modest but significant reduction in proliferation was observed with
a 1-μM dose in both SKOV3ip1 and HeyA8 to day 3 (Figure 4C ).
Cell cycle analysis showed a potent G2/M arrest in HeyA8 cells treated
with the inhibitor (Figure 4D). The next step was to determine whether
treatment with PF-2341066 could also induce cell death. HeyA8
cells were incubated with PF-2341066 or vehicle for 48 hours, and
nonadherent cells were collected. Staining of the treated cells with
Figure 2. Treatment with PF-2341066 increases survival. Female
athymic nude mice were injected i.p. with SKOV3ip1 cells and, after
8 days, were given PF-2341066 at 50 mg/kg or vehicle 6 days/week
by oral gavage. Treatment continued until mice began to show
signs of distress and then mice were killed and the presence of tu-
mor was confirmed. All living mice were killed after 10 weeks of
survival, and the presence of tumor was confirmed. Survival curves
were calculated using Kaplan-Meier. Treatment with PF-2341066
significantly improved the overall survival of cancer-bearing mice
(P = .0003). Control n = 9, treated (PF) n = 10.
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Hoechst 33342 showed nuclear condensation and DNA fragmenta-
tion (Figure 4E , left), hallmarks of apoptotic cell death. In addition,
flow cytometry analysis of cells stained with propidium iodide showed
a near two-fold increase in apoptotic cell population in treated cells
(Figure 4E , right).
Discussion
The therapeutic efficacy of c-Met inhibition has been studied in a
number of preclinical models. However, many of the inhibitors stud-
ied are not suitable for patient treatment because of poor pharmaceu-
tical properties [12]. PF-2341066 is a highly specific, orally available,
c-Met inhibitor that is presently in phase 1/2 clinical studies and
could be considered for clinical use in ovarian cancer. Herein we
show that treatment with the inhibitor abrogates HGF-stimulated
c-Met activation and downstream signaling as well as branching
morphogenesis. Furthermore, PF-2341066 reduced proliferation, ad-
hesion, and protease expression and induced apoptosis. To the best of
our knowledge, this is the first study to show that a small-molecule
inhibitor targeting c-Met, PF-2341066, is effective in reducing tumor
burden and increasing survival in a preclinical model of ovarian cancer.
The invasive growth program initiated by HGF activation of
c-Met has been shown to be dependent on the coordinated activation
of both the Ras and PI3K pathways [29]. Although c-Met phosphor-
ylation could be similarly inhibited by PF-2341066 in all cell lines
tested, differential behavior of downstream signaling pathways was
observed. Notably, phosphorylation of Erk1/2 was not affected by
HGF stimulation or c-Met inhibition in HeyA8 cells compared with
Figure 3. PF-2341066 inhibits c-Met and downstream signaling in vitro. (A) Western blot showing expression of ALK in CaOV3, SKOV3ip1,
and HeyA8 cell lines using an antibody that recognizes both wild type and fusion ALK proteins. SUDHL-1 is a positive control expressing
NPM-ALK and does not express full-length ALK. (B) Western blots showing expression of c-Met and downstream signaling proteins. The
ovarian cancer cell lines, CaOV3, SKOV3ip1, and HeyA8, were serum-starved for 24 hours and then pretreated with the indicated con-
centrations of PF-2341066 for 1 hour before stimulation with 40 ng/ml HGF for 10 minutes. (C) Western blots of phospho-proteins;
c-Met, Gab-1, Src, and FAK. HeyA8 cells were serum-starved for 24 hours before treating with 1 μM PF-2341066 or vehicle. (D) Branching
morphogenesis assay. SKOV3ip1 and HeyA8 cells were mixed with Matrigel, plated, and cultured for 4 days in complete medium supple-
mented with 40 ng/ml HGF with or without 1 μM PF-2341066. Original magnification, ×20.
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SKOV3ip1 cells. A possible explanation for this effect might be that
the HeyA8 cell line contains a BRAF mutation that results in consti-
tutive activation of the Ras/Raf/Erk pathway [30]. Further analysis
of downstream signaling in HeyA8 cells revealed that activation of
the signal transducers, Gab-1 and Src, was both reduced with PF-
2341066 treatment. Phosphorylation of c-Met at site 1349 has been
shown to be critical for Gab-1 and Src binding and, consequently,
necessary for c-Met’s biologic function [31–33]. Therefore, these
findings suggest that PF-2341066 is sufficient to inhibit c-Met de-
pendent growth and morphogenesis.
The in vivo studies showed that, tumor weight was inhibited by
55% and the number of metastases was inhibited by approximately
63%. These data are consistent with the report from Saga et al. [34],
which showed an approximate 70% inhibition of metastasis with an
ovarian cancer cell line stably transfected with the HGF competitive
molecule, NK4. In addition, we previously reported that silencing of
c-Met through siRNA treatment in an in vivo model of ovarian can-
cer resulted in an 85% inhibition of tumor nodules, tumor weight,
and ascites volume [6]. Owing to the specific nature of siRNA as well
as the use of the identical cell line in both studies, the comparable
effects observed with PF-2341066 treatment can likely be attributed
to the specific inhibition of c-Met. Other small-molecule inhibitors
of c-Met have been shown to be effective in preclinical models of
lung cancer [35] and in models of metastasis [16], which supports
the therapeutic relevance of targeting c-Met. Zou et al. [19] showed
that treatment with PF-2341066 was sufficient to inhibit 100% of
tumor growth in a subcutaneous mouse model. As a strategy to by-
pass the problem of the incompatibility of mouse HGF with human
c-Met, the authors used models with constitutively active c-Met. For
example, the GTL-16 cell line is a human gastric carcinoma that
expresses high levels of constitutively active c-Met and the U87G hu-
man glioblastoma cell line expresses both HGF and c-Met, compris-
ing an autocrine loop. The dependency of these cell lines on c-Met
makes them useful for the study of c-Met inhibition by PF-2341066.
However, it is likely that these cell line models are representative of
only a subset of very c-Met–dependent cancers.
In our model, c-Met is not constitutively active, nor does it express
HGF (data not shown). Therefore, this model probably represents
a wider range of ovarian cancers (and other tumors) in which HGF–
c-Met signaling is only one of many activators of oncogenic signaling
pathways contributing to tumorigenesis. That the inhibitor only re-
duced tumor growth and metastasis by around 60% indicates that
oncogenic pathways other than c-Met are important in the growth
of ovarian cancer cells. Therefore, combining a c-Met inhibitor with
other targeted treatments or chemotherapy might be an effective next
step in ovarian cancer therapeutics. Obvious candidates for combined
therapy with PF-2341066 are paclitaxel and carboplatin, the drugs
commonly used for ovarian cancer treatment.
Figure 3. (continued).
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Figure 4. PF-2341066 inhibits proliferation, adhesion, and invasion and induces cell death in ovarian cancer cell lines. (A) Adhesion assay.
In vitro adhesion assay to ECM components. SKOV3ip1 and HeyA8 cells were fluorescently labeled with CMFDA and then pretreated with
10 μM PF-2341066 for 10 minutes. After incubation for 30 minutes with the indicated ECMs, the number of adhesive cells was determined
using a fluorescence reader. *P < .01, **P < .0001. (B) Gelatin zymogram. Tumors from mice treated with either PF-2341066 or vehicle
(control) were lysed in RIPA buffer and resolved on a 10% SDS-PAGE gel containing gelatin. HT-1080 conditioned medium served as a
positive control. (C) Proliferation assay. SKOV3ip1 and HeyA8 cells were plated in complete mediumwith either 1 μMPF-2341066 or vehicle
and assayed at the indicated time points. *P< .005, **P< .0001, ***P< .00001. (D) Cell cycle analysis. HeyA8 cells were serum-starved for
24 hours before treating with PF-2341066 for 24 hours. Cells were then stained with propidium iodide and analyzed using a flow cytometer.
The percentage of cells in each phase of the cell cycle is shown. (E) Nuclear fragmentation (left). SKOV3ip1 cells were treated for 48 hours
with 10 μMPF-2341066 or vehicle. Nonadherent cells were collected by centrifugation and stainedwith 2 μMHoechst 33342 to visualize cell
death. Cells were visualized at a magnification of ×20. Quantification of apoptosis by flow cytometry (right). Cells were treated for 48 hours
with 10 μM PF-2341066 or vehicle, stained with propidium iodide, and analyzed using a flow cytometer. Percent of sub-G1 is indicated.
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Whereas PF-2341066 has also been shown to inhibit oncogenic
fusion and mutant variants of ALK [18], these proteins have most
frequently been reported to be expressed in ALK-positive cases of
ALCL, inflammatory myofibroblastic tumors, and, more recently, a
small subset of solid tumors [36–38]. We did not find evidence of
expression in ovarian cancer cell lines, and an extensive search of the
literature revealed no evidence of ALK expression or activity in adult
ovarian tissues. ALK is shown to have only low expression in adult
mammalian tissues, and whereas ALK fusion proteins are shown to
have oncogenic properties in ALCL, no pathologic function of wild
type ALK has been described [39]. Despite the noted importance of
ALK in neuronal development (reviewed in Allouche [40]), the phys-
iological role of ALK in the adult has not yet been fully elucidated
because ALK-null mice are shown to exhibit a normal phenotype
[37]. These findings suggest that there may be few off-target adverse
effects in adult patients treated with PF-2341066.
In summary, this study shows that PF-2341066 effectively reduces
tumor burden, thereby increasing median survival time, in an in vivo
model of ovarian cancer metastasis. The data presented here indicate
that PF-2341066 should be studied further as a potential therapeutic
in ovarian cancer. Last but not least, the oral availability of PF-
2341066 offers patients a mode of administration far less inconve-
nient and uncomfortable than intravenous treatments.
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